Concepedia

Reshma Rangwala

RR

Statistics

Publications

30

Citations

20.2K

H-Index

22

Active since

2002

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

The University of Sydney

Westmead Hospital

University of Pennsylvania

Meir Medical Center

Reshma Rangwala is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and chemotherapy.

Publications per year

2002–2023

30

Publications

30

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text

, , +17

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text

, , +17

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

Jean‐Sébastien Frenel, Christophe Le Tourneau, Bert H. O’Neil et al. · Journal of Clinical Oncology · 2017 · 534 citations

, , +14

Combined MTOR and autophagy inhibition

Reshma Rangwala, Yunyoung C Chang, Janice Hu et al. · Autophagy · 2014 · 419 citations · Full text

, , +17

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Robert L. Coleman, Domenica Lorusso, Christine Gennigens et al. · The Lancet Oncology · 2021 · 394 citations

, , +13

1–5 of 30